Evan David Seigerman
Stock Analyst at BMO Capital
Total Price Targets
38
Stocks Covered
13
Sectors
Healthcare
Most Recent
Mar 9, 2026
Notable Calls (Last 12 Months)
Most Bullish
Stocks Covered by Evan David Seigerman
| Symbol | Company | Latest Target | Current Price | Upside | # Targets | Last Updated |
|---|---|---|---|---|---|---|
| PFE | Pfizer Inc. | $30.00 | $26.38 | +13.7% | 1 | Mar 9, 2026 |
| VRTX | Vertex Pharmaceuticals Incorporated | $600.00 | $425.06 | +41.2% | 3 | Mar 2, 2026 |
| GILD | Gilead Sciences, Inc. | $150.00 | $132.04 | +13.6% | 5 | Jan 26, 2026 |
| ABBV | AbbVie Inc. | $258.00 | $206.29 | +25.1% | 3 | Jan 15, 2026 |
| IRON | Disc Medicine, Inc. | $112.00 | $67.31 | +66.4% | 3 | Nov 5, 2024 |
| BMY | Bristol-Myers Squibb Company | $57.00 | $58.22 | -2.1% | 3 | Nov 1, 2024 |
| MRK | Merck & Co., Inc. | $136.00 | $111.89 | +21.5% | 4 | Nov 1, 2024 |
| REGN | Regeneron Pharmaceuticals, Inc. | $1190.00 | $703.72 | +69.1% | 4 | Nov 1, 2024 |
| NBIX | Neurocrine Biosciences, Inc. | $121.00 | $131.64 | -8.1% | 2 | Oct 31, 2024 |
| LLY | Eli Lilly and Company | $1010.00 | $961.67 | +5.0% | 4 | Oct 31, 2024 |
| AMGN | Amgen Inc. | $362.00 | $328.69 | +10.1% | 3 | Sep 25, 2024 |
| BIIB | Biogen Inc. | $260.00 | $186.69 | +39.3% | 2 | May 23, 2024 |
| INCY | Incyte Corporation | $52.00 | $96.41 | -46.1% | 1 | Apr 30, 2024 |
Recent Activity
- Mar 9, 2026— Set$30.00price target onPFE(Pfizer Inc.)
- Mar 2, 2026— Set$600.00price target onVRTX(Vertex Pharmaceuticals Incorporated)
- Jan 26, 2026— Set$150.00price target onGILD(Gilead Sciences, Inc.)
- Jan 15, 2026— Set$258.00price target onABBV(AbbVie Inc.)
- Nov 25, 2025— Set$135.00price target onGILD(Gilead Sciences, Inc.)
- Nov 12, 2024— Set$208.00price target onABBV(AbbVie Inc.)
- Nov 5, 2024— Set$112.00price target onIRON(Disc Medicine, Inc.)
- Nov 1, 2024— Set$57.00price target onBMY(Bristol-Myers Squibb Company)
- Nov 1, 2024— Set$1190.00price target onREGN(Regeneron Pharmaceuticals, Inc.)
- Nov 1, 2024— Set$136.00price target onMRK(Merck & Co., Inc.)
- Oct 31, 2024— Set$121.00price target onNBIX(Neurocrine Biosciences, Inc.)
- Oct 31, 2024— Set$1010.00price target onLLY(Eli Lilly and Company)
- Oct 31, 2024— Set$228.00price target onABBV(AbbVie Inc.)
- Oct 21, 2024— Set$94.00price target onGILD(Gilead Sciences, Inc.)
- Oct 21, 2024— Set$566.00price target onVRTX(Vertex Pharmaceuticals Incorporated)
- Sep 25, 2024— Set$362.00price target onAMGN(Amgen Inc.)
- Sep 23, 2024— Set$48.00price target onBMY(Bristol-Myers Squibb Company)
- Sep 13, 2024— Set$128.00price target onNBIX(Neurocrine Biosciences, Inc.)
- Sep 12, 2024— Set$1300.00price target onREGN(Regeneron Pharmaceuticals, Inc.)
- Aug 9, 2024— Set$1101.00price target onLLY(Eli Lilly and Company)
Frequently Asked Questions
Who is Evan David Seigerman?
Evan David Seigerman is a stock analyst at BMO Capital covering 13 stocks primarily in Healthcare. They have issued 38 price targets since Feb 13, 2022.
What stocks does Evan David Seigerman cover?
Evan David Seigerman currently covers 13 stocks, including GILD, MRK, REGN, LLY, VRTX.
What is Evan David Seigerman's latest price target?
Evan David Seigerman's most recent price target was $30.00 on PFE (Pfizer Inc.), set on Mar 9, 2026.
What is Evan David Seigerman's highest price target?
Evan David Seigerman's highest issued price target is $1300.00 on REGN, set on Sep 12, 2024.
More Analysts at BMO Capital
Coverage based on publicly published price targets. Not investment advice.